Clinical and biological significance of RAS mutations in multiple myeloma

Leukemia

Volumn 22, Issue 12, 2008, Pages 2280-2284

  Chng, W J ^a,f,g   Gonzalez Paz, N ^b   Price Troska, T ^b   Jacobus, S ^c   Rajkumar, S V ^b   Oken, M M ^d   Kyle, R A ^b   Henderson, K J ^b   Van Wier, S ^a   Greipp, P ^b   Van Ness, B ^e   Fonseca, R ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d North Memorial Cancer Center   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f Dept Medicine Endocrinol Diabet   (Singapore)

^g NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; K RAS PROTEIN; RAS PROTEIN;

CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DNA DETERMINATION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GEL ELECTROPHORESIS; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; LETTER; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

EID: 57849129292     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.142     Document Type: Letter

References (8)

1. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007; 20: 571-596.
2. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-4575.
3. Greipp PR, Trendle MC, Leong T, Oken MM, Kay NE, Van Ness B et al. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma 1999; 35: 83-89.
4. Oken MM, Leong T, Lenhard Jr RE, Greipp PR, Kay NE, Van Ness B et al The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: Phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer 1999; 86: 957-968.
5. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005; 105: 317-323.
6. Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001; 18: 212-224.
7. Kalakonda N, Rothwell DG, Scarffe JH, Norton JD. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood 2001; 98: 1555-1560.
8. Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007; 21: 582-584.